42 results about "Bacillus ehimensis" patented technology

The invention provides lactobacillus crispatus, which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on February 7, 2023, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No. 26503. The bacillus subtilis can play a relatively strong role in inhibiting pathogenic bacteria such as gardnerella vaginalis, escherichia coli and staphylococcus aureus at the same time, and also has a certain role in inhibiting candida albicans, two-way proteurella and Atortoria vaginalis. Therefore, the lactobacillus crispatus has the potential of maintaining the environment in the vagina to be faintly acid and improving the mucosal immunity and infection resistance of a host, and can be used for preventing and treating vaginal infection and inflammation, and maintaining, improving or recovering the steady state of the environment in the vagina.

The invention discloses a urinary system infection pathogen and drug resistance gene detection system and a kit. The detection system comprises forward and reverse primers which are respectively used for detecting escherichia coli, staphylococcus aureus, acinetobacter baumannii, klebsiella pneumoniae, enterococcus faecium, candida glabrata, proteus mirabilis, enterococcus faecalis, candida tropicalis, enterobacter cloacae, candida albicans, pseudomonas aeruginosa and streptococcus agalactiae; the forward primer and the reverse primer are respectively used for detecting the blaCTX-M gene of the extended spectrum beta-lactamase, the forward primer and the reverse primer are used for detecting the blaSHV gene of the extended spectrum beta-lactamase, and the forward primer and the reverse primer are used for detecting the blaTEM gene of the extended spectrum beta-lactamase. According to the forward and reverse primers for detecting the blaNDM gene of the extended-spectrum beta-lactamase, a detection sample is urine. According to the invention, common gram-negative bacteria, gram-positive bacteria and fungi can be detected at the same time, and the problem of missed detection of mixed infection in traditional culture is solved.

The invention provides lactobacillus gasseri which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on February 7, 2023, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.26504. The lactobacillus gasseri has the advantages that the lactobacillus gasseri can be used for preparing the lactobacillus gasseri; the lactobacillus gasseri has a relatively strong inhibition effect on pathogenic bacteria such as Gardneria vaginalis, Escherichia coli, staphylococcus aureus and two-way Pleuromycosis, and also has a certain inhibition effect on CA, so that the lactobacillus gasseri has the effects of killing pathogenic bacteria, improving the host mucosal immunity and resisting infection, and has a good application prospect in the field of animal husbandry, animal husbandry, animal husbandry, animal husbandry, animal husbandry, animal husbandry, animal husbandry and animal husbandry. Meanwhile, growth and reproduction of harmful bacteria can be inhibited, vaginal infection is prevented, and inflammation is treated.

The invention provides a microorganism, which is Lactobacillus jensenii, is preserved in the China General Microbiological Culture Collection Center on February 7, 2023, and has the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.26505. The invention further provides a preparation method of the microorganism. The lactobacillus jensenii has a relatively strong inhibition effect on pathogenic bacteria such as gardnerella vaginalis, escherichia coli, staphylococcus aureus and two-way proteurella, so that the lactobacillus jensenii has the capabilities of maintaining the weak acidity of the environment in the vagina and further resisting invasion of other pathogenic bacteria, and can be used for preventing and treating vaginal infection and inflammation; the steady state of the environment in the vagina is maintained, improved or recovered.

The invention belongs to the field of plant endophytic fungus secondary metabolites, particularly relates to a secondary metabolite of fennel endophytic fungus fusarium oxysporum as well as a preparation method and application thereof, and provides a fennel endophytic fungus secondary metabolite with structures as shown in compounds 1-8. Wherein the compound 2 and the compound 7 have inhibitory activity on staphylococcus aureus, escherichia coli, bacillus cereus, bacillus subtilis, candida albicans and shigella, and have a certain inhibitory effect on cervical cancer Hela cell strains.

The invention belongs to the technical field of biology, and particularly relates to a primer probe composition and a kit for detecting lower respiratory tract infection pathogens. The primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae, and the primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae. The composition is one or more of a composition for detecting staphylococcus aureus, a composition for detecting streptococcus pneumoniae, a composition for detecting escherichia coli, a composition for detecting moraxella catarrhalis, a composition for detecting serratia marcescens, a composition for detecting mycoplasma pneumoniae, a composition for detecting candida albicans or a composition for detecting adenovirus; the RAA-RDB technology has the core advantages of rapidness, high sensitivity, low cost and easy operation, and is especially suitable for multiple pathogen screening and basic medical application.

The present invention relates to the pharmaceutical field, and provides a boric acid β-lactamase inhibitor or a use thereof. The boric acid β-lactamase inhibitor is a compound shown in formula (I), or an optical isomer or a pharmaceutically acceptable salt thereof: formula (I). The ultra-broad-spectrum boric acid β-lactamase inhibitor of the present invention has an inhibition effect on A, B, C, and D enzymes, and carbapenem drug-resistant bacteria such as Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, Acinetobacter baumannii, and Pseudomonas aeruginosa.

The invention provides a primer combination of a multiple detection kit for food-borne pathogenic bacteria and the multiple detection kit. The primer combination comprises probes and primers for detecting nine food-borne pathogenic bacteria: vibrio cholerae general type, vibrio cholerae O1 type, vibrio cholerae O139 type, vibrio parahaemolyticus, salmonella, yersinia enterocolitica, campylobacter, listeria monocytogenes and enterobacter sakakaakii, and the sequence is shown as SEQ1-31; the probe and the primer pair are used for detecting nine characteristic genes, namely a shigella universal type: ipaH, a diarrheogenic Escherichia coli universal type: eltA, sta3, sta and aggR, and enterohemorrhagic Escherichia coli: stx1, stx2, escV and rfbE, and the sequences of the probe and the primer pair are shown as SEQ32-64. According to the invention, by combining a digital PCR multiple coding technology, the detection of 12 food-borne pathogenic bacteria can be realized, and the sensitivity, the specificity and the accuracy are relatively good.

The invention belongs to the technical field of bacterium detection, and discloses a multiple PCR primer for simultaneously detecting eight respiratory tract pathogenic bacteria and application thereof. On the basis of a Luminex liquid phase chip technology, specific primers are designed aiming at eight common respiratory tract infection pathogenic bacteria including pseudomonas aeruginosa, staphylococcus aureus, streptococcus pneumoniae, klebsiella pneumoniae, acinetobacter baumannii, stenotrophomonas maltophilia, haemophilus influenzae and escherichia coli; the multiple PCR primers which are high in amplification efficiency, good in specificity and suitable for simultaneously detecting the eight respiratory tract pathogenic bacteria are screened out, the multiple PCR system and microsphere hybridization conditions are continuously optimized, the multiple PCR method for the eight respiratory tract pathogenic bacteria is successfully constructed by applying the Luminex xTAG technology, and the multiple PCR method can be applied to rapid detection of multiple pathogenic microorganisms.

The invention relates to the technical field of functional food, and particularly discloses a preparation method and application of origanum vulgare essential oil oral nanoemulsion, the preparation method comprises the following steps: by taking origanum vulgare essential oil as an oil phase, PEG-40 hydrogenated castor oil as a surfactant and propylene glycol as a cosurfactant, determining the mass ratio of the surfactant to the cosurfactant to be 5: 1 through optimization, and preparing the origanum vulgare essential oil oral nanoemulsion. And determining the final prescription composition by using the quasi-ternary phase diagram. The oregano essential oil oral nano-emulsion provided by the invention is a faint yellow transparent clarified liquid, is good in stability, has a remarkable bacteriostatic effect on staphylococcus aureus and escherichia coli, solves the problems of poor water solubility, poor stability and strong oral irritation of the oregano essential oil, and provides a good basis for the application of the oregano essential oil as an oral preparation.

The invention belongs to the technical field of microorganisms, and particularly relates to a bacterial strain for promoting formation of calculus bovis, a microbial agent and application of the bacterial strain, the bacterial strain is classified and named as Escherichia fergusonii, the bacterial strain is preserved in China General Microbiological Culture Collection Center on May 13, 2025, and the preservation number is CGMCC No.34526. The invention further discloses a preparation method of the bacterial strain for promoting formation of calculus bovis. The strain can be used as a transformation strain for in-vitro cultivation of calculus bovis and can also be used as an implantation strain for artificial in-vivo cultivation of calculus bovis, and the problems that in the process of artificial in-vitro cultivation or in-vivo cultivation of calculus bovis, thalli are low in bile tolerance and enzyme production activity, short in survival time in ox bile and low in calculus bovis forming efficiency are solved.

The invention discloses an application of a strobilanthes guineensis extract in bacteriostasis, and belongs to the technical field of traditional Chinese medicine extraction, and the strains capable of being inhibited comprise bacillus subtilis, staphylococcus aureus, pseudomonas aeruginosa and escherichia coli; the strobilanthes laxiflora extract comprises a water extract, a water extraction and alcohol precipitation extract and a chloroform extract according to different extraction modes; according to the invention, it is proved that the lauberine has an inhibition effect on bacillus subtilis, staphylococcus aureus, pseudomonas aeruginosa and escherichia coli, has a certain antibacterial effect, and provides a reference basis for further research on the antibacterial activity of the lauberine.

The present invention relates to the application of creatmycin in inhibiting gastrointestinal tract pathogenic bacteria, and the gastrointestinal tract pathogenic bacteria include but are not limited to: Helicobacter pylori, Clostridium difficile, Bacteroides fragilis, Escherichia fergusonii, Clostridium sporogenes.

The invention relates to the field of inspection and detection of dalbavancin, in particular to a microbial limit inspection method of dalbavancin. Comprising the following steps: S1, preparation of a test solution: dissolving a test sample with sterilized water, and respectively preparing a 1: 10 test solution and a 1: 50 test solution; s2, checking the total number of aerobic bacteria and the total number of mould and saccharomycetes; and S3, inspection of control bacteria Escherichia coli. The technical problem to be solved by the invention is to provide the microbial limit detection method for the dalbavancin, which is scientific and effective and is beneficial to detection, so that the microbial limit quality of the dalbavancin variety is controllable. According to the invention, sterile water is screened as a diluent, so that the problem of dissolution of the dalbavancin bulk drug is solved, and the recovery ratio of test bacteria is increased; a membrane filtration method is adopted, a proper neutralizer is added into a flushing fluid, and a proper neutralizer is added into a TSA / SDA culture medium of a film, so that the antibacterial activity of the dalbavancin is effectively removed, and the recovery ratio of five test bacteria in microbe counting meets the requirements of pharmacopeia.

The present invention relates to the field of antimicrobial peptide application technology, and more specifically to an antimicrobial peptide MA25 with broad-spectrum antimicrobial activity and its applications. The amino acid sequence of the antimicrobial peptide MA25 is shown in SEQ ID NO. 1. The antimicrobial peptide MA25 of the present invention has antimicrobial activity against a variety of bacteria (Staphylococcus aureus, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae) and their drug-resistant strains, and has excellent biosafety and physiological stability. It has broad development prospects and can be used in alternative treatments for bacterial infections or in bacteriostatic or bactericidal applications.

The invention belongs to the technical field of microorganisms, and particularly relates to Escherichia coli MZ2014 with sustainable phenotypic heterogeneity and heterogeneity drug resistance characteristics and application of the Escherichia coli MZ2014. The MZ2014 strain can be continuously and stably differentiated into two forms of a large bacterial colony (MZ2014-B) and a small bacterial colony (MZ2014-S) under conventional culture conditions, and the two subgroups show a clear heterogeneity drug-resistant phenotype: the MZ2014-B is shown as a medium for ertapenem, and the MZ2014-S is shown as sensitivity. Further researches show that the two subgroups have significant differences in cellular morphology, growth rate and athletic ability. Therefore, the MZ2014 strain provided by the invention is not only a precious model for researching phenotypic heterogeneity and non-hereditary drug resistance mechanisms, but also can be used as a key tool for screening active substances capable of overcoming heterogeneity drug resistance or inhibiting phenotypic differentiation, and has important scientific research value and application prospect.

The invention relates to the technical field of biotechnology, in particular to an extraction and filtration method of ginseng fruit total saponin powder, which specifically comprises the following steps: sequentially carrying out water extraction, pH value regulation, centrifugation, purification, concentration, drying, crushing and mixing on ginseng fruit pulp, and finally extracting to obtain the ginseng fruit total saponin powder with the yield of 0.76-0.80%. The concentration of ginsenoside Re in the ginseng fruit total saponin powder is not lower than 650 mg / g, the concentration of microorganism aerobic bacteria is smaller than or equal to 800 cfu / g, the concentration of mould and saccharomycetes is smaller than or equal to 80 cfu / g, and no Escherichia coli is detected, so that the validity period of the ginseng fruit total saponin powder is greatly prolonged and can reach 36 months in a sealed and moistureproof environment.

The application discloses a bacteriophage cocktail for treating or preventing high-risk clonal strains of companion animals and application thereof. The application provides a bacteriophage cocktail containing bacteriophages 32M3Y, CRE5643Y, 3BB6Y and S17S. Through simulating the mechanism of resistance occurrence in the bacteriophage treatment process, the second round of bacteriophage screening is carried out on the bacteriophage-resistant strains. The obtained candidate bacteriophages can lyse the resistant strains of high-risk clonal strains of Escherichia coli. The composition composed of the candidate bacteriophages can inhibit the resistance evolution of the bacteria in the bacteriophage treatment process, can avoid the emergence of the bacteriophage-resistant strains with enhanced virulence in the bacteriophage treatment process, has the effect of preventing and treating pet clinical ST410 type strain infection, and can be used for environmental disinfection. Through blocking the transmission chain of drug-resistant bacteria in the domestic environment (pets-human-environment), the risk of human-animal coexistence can be significantly reduced.

The invention relates to a flora prediction model for detecting premature delivery risk and a kit and application thereof. Through early-stage mNGS data collection and analysis, premature related strains are obtained, and through a large number of experimental screening and optimization, a set of optimal primer probe group is finally determined. The invention relates to a premature delivery risk calculation method, which comprises the following steps of: selecting 12 floras, namely lactobacillus crispatus, lactobacillus gasseri, lactobacillus inertus, lactobacillus jensenii, escherichia coli, enterococcus faecalis, enterobacter aerogenes, group B hemolytic streptococcus, ureaplasma parvum, chlamydia trachomatis, diplococcus gonorrhoeae and gardnerella vaginalis, and establishing a fluorescent quantitative PCR (Polymerase Chain Reaction) method and a premature delivery risk calculation model aiming at the detection of the 12 floras. Compared with an existing detection method, the method is simple, convenient, rapid, high in sensitivity and high in specificity, the false positive and false negative risk is reduced, and the purpose of batch detection is achieved. Clinically, the change of microbial flora in the reproductive system of a pregnant woman can be rapidly detected, corresponding treatment measures are taken, the risk of PTB occurrence is reduced, and the kit has a good application prospect.

This invention belongs to the field of microbial technology, specifically relating to the multifunctional Lactobacillus curvatureii and its application in the preparation of health products. The Lactobacillus curvatureii (… Lactobacillus crispatus Lactobacillus crispatus The accession number for MCOlact00102 is CGMCC No. 34381. The described *Lactobacillus curvatureensis* (MCOlact00102) is... Lactobacillus crispatus ​ The two strains, MCOlact00126 (CGMCC No. 34382), exhibit significant inhibitory effects against bacterial vaginosis (BV) and infections caused by Gardnerella vaginalis, Group B Streptococcus (GBS), Escherichia coli, or Candida albicans. The safety of these strains was evaluated using a 3D vaginal epithelial organoid model, showing no irritant effect on cells. Furthermore, hemolytic activity tests, antibiotic resistance gene detection, and functional validation all demonstrated their good safety profile. In addition, the aerobic acclimation process significantly improved the stability and bioactivity of these two strains in actual production and clinical applications, laying a solid foundation for their industrialization and application.

The invention relates to the technical field of antibacterial peptide application, in particular to an antibacterial peptide MM19 with broad-spectrum antibacterial activity and application of the antibacterial peptide MM19. The amino acid sequence of the antibacterial peptide MM19 is as shown in SEQ ID NO. 1. The antibacterial peptide MM19 disclosed by the invention has antibacterial activity on various bacteria (staphylococcus aureus, escherichia coli, acinetobacter baumannii, pseudomonas aeruginosa and klebsiella pneumoniae) and drug-resistant strains thereof, is excellent in biological safety and physiological stability, and has a wide development prospect; the compound can be used for alternative treatment of bacterial infection or used for application scenarios of bacteriostasis or sterilization.

The invention relates to the technical field of conjugational transfer engineering bacteria, in particular to a conjugational transfer donor bacterium as well as a construction method and application thereof, the conjugational transfer donor bacterium is Escherichia fergusonii EFmg-sy, is preserved in the China Center for Type Culture Collection (CCTCC), and has the preservation number of CCTCC NO: M2025310; the invention relates to a conjugational transfer donor bacterium which is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of CCTCC NO: M20251730, or the conjugational transfer donor bacterium is Escherichia fergusonii EFmg-cj and is preserved in China Center for Type Culture Collection (CCTCC). The conjugational metastasis donor bacterium provided by the invention is stable in character, is simple to operate as a conjugational metastasis donor, and can be used for rapidly detecting and distinguishing the conjugational metastasis donor bacterium and a recipient bacterium receiving plasmids through a fluorescence detection method, so that the detection of the plasmid horizontal transfer capability of the Escherichia fjosenii is realized.

The application discloses a solubilization-stable liquid preparation of Trollius chinensis Bunge and a preparation method thereof. Anionic surfactant is used as a micelle carrier. Through a stable micelle structure formed in the water phase, the poorly soluble active ingredients in Trollius chinensis Bunge extract are dissolved and uniformly dispersed in the water phase, so that the solubility and system stability are significantly improved, and the bacteriostatic effect is improved. Through screening of formula components and optimization and adjustment of the composition ratio, the application successfully prepares a clear liquid preparation with excellent bacteriostatic activity from the poorly soluble substances of Trollius chinensis Bunge. The inhibition rate of the preparation on Escherichia coli, Staphylococcus aureus and Candida albicans is more than 90% after 30s of contact. The preparation has good stability after being placed at room temperature for 24 months, and the inhibition rate on the three test bacteria is still more than 80%. The concentration of Trollius chinensis Bunge extract required to achieve the same or even better bacteriostatic effect is far lower than 1 / 16 of the Trollius chinensis Bunge liquid preparation assisted by dimethyl sulfoxide (DMSO) organic solvent.

This invention discloses an antimicrobial 10-peptide, characterized by the sequence: w-k-r-w-r-r-w-w-r-r(dTrp-dLys-dArg-dTrp-dArg-dArg-dTrp-dTrp-dArg-dArg), where all amino acids are D-type amino acids. The antimicrobial peptide provided by this invention exhibits good antimicrobial activity against a variety of pathogenic bacteria. This antimicrobial peptide can be synthesized using the Fmoc solid-phase chemical method, which is easy to synthesize and exhibits good in vivo antimicrobial activity. This antimicrobial peptide exhibits broad-spectrum killing activity against multidrug-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, as well as standard strains of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, methicillin-resistant Staphylococcus aureus, and Staphylococcus aureus. It has low hemolytic toxicity, and at low to medium concentrations (2 μg / mL to 32 μg / mL), the cell survival rate can reach more than 50%. It has no toxic effect on cells, good stability, strong operability, and low cost.

The present invention relates to the field of antimicrobial peptide application technology, and more specifically to an antimicrobial peptide MM19 with broad-spectrum antimicrobial activity and its applications. The amino acid sequence of the antimicrobial peptide MM19 is shown in SEQ ID NO. 1. The antimicrobial peptide MM19 of the present invention has antimicrobial activity against a variety of bacteria (Staphylococcus aureus, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae) and their drug-resistant strains, and has excellent biosafety and physiological stability. It has broad development prospects and can be used in alternative treatments for bacterial infections or in antibacterial or bactericidal applications.

The invention relates to the technical field of antibacterial peptide application, in particular to an antibacterial peptide MA25 with broad-spectrum antibacterial activity and application of the antibacterial peptide MA25. The amino acid sequence of the antibacterial peptide MA25 is as shown in SEQ ID NO. 1. The antibacterial peptide MA25 disclosed by the invention has antibacterial activity on various bacteria (staphylococcus aureus, escherichia coli, acinetobacter baumannii, pseudomonas aeruginosa and klebsiella pneumoniae) and drug-resistant strains thereof, is excellent in biological safety and physiological stability, and has a wide development prospect; the compound can be used for alternative treatment of bacterial infection or used for application scenarios of bacteriostasis or sterilization.

The invention relates to the technical field of biology, in particular to a rapid detection kit for bacterial food-borne pathogenic microorganisms and application of the rapid detection kit. The invention develops a primer probe combination kit for detecting food-borne bacteria salmonella, staphylococcus aureus, vibrio parahaemolyticus, listeria monocytogenes, escherichia coli O157 and clostridium perfringens through optimization of primers, optimization of hydrogel components and a system and the like. The primer probe combination kit is used for detecting food-borne bacteria salmonella, staphylococcus aureus, vibrio parahaemolyticus, listeria monocytogenes, escherichia coli O157 and clostridium perfringens. The kit is used for detecting salmonella, staphylococcus aureus, vibrio parahaemolyticus, listeria monocytogenes, Escherichia coli O157 and clostridium perfringens. The kit is high in sensitivity and specificity, strong in anti-interference capability, excellent in stability and portability, rapid and efficient in detection, simple and convenient to operate and low in cost, and can realize result visualization and relative quantification, so that the kit has wide application prospects and values.

The invention relates to the technical field of antibacterial peptide application, in particular to an antibacterial peptide GK18 with broad-spectrum antibacterial activity and application of the antibacterial peptide GK18. The amino acid sequence of the antibacterial peptide GK18 is as shown in SEQ ID NO. 1. The antibacterial peptide GK18 disclosed by the invention has antibacterial activity on various bacteria (staphylococcus aureus, escherichia coli, acinetobacter baumannii, pseudomonas aeruginosa and klebsiella pneumoniae) and drug-resistant strains thereof, is excellent in biological safety and physiological stability, and has a wide development prospect; the compound can be used for alternative treatment of bacterial infection or used for application scenarios of bacteriostasis or sterilization.

The invention discloses bacteriophage lyase and application thereof in preparation of an antibacterial agent. The bacteriophage lyase has a remarkable splitting effect on gram-negative bacteria, so that the bacteriophage lyase can be used as a broad-spectrum antibacterial protein. For example, the antibacterial effect on gram-negative bacteria such as escherichia coli, pseudomonas aeruginosa and klebsiella pneumoniae is remarkable. The antibacterial protein has relatively high temperature tolerance and pH tolerance, can replace antibiotics, and is applied to prevention and treatment of bacterial diseases as an external medicine or an internal medicine and sterilization of medical instruments and medical places; and the product can also be used as an additive to be applied to the fields of feed processing, food industry, animal husbandry, beer industry, aquaculture, cosmetic production, fruit preservation and the like.

The present invention relates to the field of antimicrobial peptide application technology, and specifically to an antimicrobial peptide GK18 with broad-spectrum antimicrobial activity and its application. The amino acid sequence of the antimicrobial peptide GK18 is shown in SEQ ID NO. 1. The antimicrobial peptide GK18 of the present invention has antimicrobial activity against a variety of bacteria (Staphylococcus aureus, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae) and their drug-resistant strains, and has excellent biosafety and physiological stability. It has broad development prospects and can be used in alternative treatments for bacterial infections or in bacteriostatic or bactericidal applications.